Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-029197
Filing Date
2025-02-27
Accepted
2025-02-27 17:00:03
Documents
1
Period of Report
2025-02-25

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3150
  Complete submission text file 0000950170-25-029197.txt   4913
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Issuer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O GENOCEA BIOSCIENCES, INC. 100 ACORN PARK DRIVE 5TH FLOOR CAMBRIDGE MA 02140
Business Address
SUMER JACQUELYN L (Reporting) CIK: 0001844824 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 25680406